九典制藥(300705.SZ):力爭打造“久悦”貼膏品牌 提升品牌價值
格隆匯7月6日丨九典制藥(300705.SZ)近期在接待機構調研時表示,公司在局部經皮給藥領域佈局了多個消炎鎮痛類的產品。從市場規劃上來考量,不同的終端板塊會有不同的佈局,每一個板塊銷售策略不一樣,定價體系也不一樣,佈局的產品也會不同。洛索洛芬鈉凝膠貼膏一直以來主要是在院內市場銷售,已經在拓展OTC渠道。總的來説,公司的研發佈局後續將形成一個良好的產品梯隊,力爭打造“久悦”貼膏品牌,提升品牌價值。待產品佈局完善後,我們相信公司在經皮給藥領域會取得不錯的成績。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.